Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.

Nicolas-Virelizier E, Ségura-Ferlay C, Ghesquières H, Chassagne-Clément C, Gargi T, Biron P, Belhabri A, Rey P, Faurie P, Chabaud S, Sebban C.

Hematol Oncol. 2015 Mar;33(1):1-8. doi: 10.1002/hon.2130. Epub 2014 Feb 5.

PMID:
24496668
2.

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. Review.

PMID:
22258971
3.

Outcomes of Treatment in Slovene Follicular Lymphoma Patients.

Južnič Šetina T, Borštnar S, Jezeršek Novaković B.

Clin Lymphoma Myeloma Leuk. 2015 Oct;15(10):586-91. doi: 10.1016/j.clml.2015.07.631. Epub 2015 Aug 3.

4.

Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.

Peters AC, Duan Q, Russell JA, Duggan P, Owen C, Stewart DA.

Leuk Lymphoma. 2011 Nov;52(11):2124-9. doi: 10.3109/10428194.2011.594925. Epub 2011 Jul 8.

PMID:
21740097
5.

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.

Zinzani PL, Khuageva NK, Wang H, Garicochea B, Walewski J, Van Hoof A, Soubeyran P, Caballero D, Buckstein R, Esseltine DL, Theocharous P, Enny C, Zhu E, Elsayed YA, Coiffier B.

J Hematol Oncol. 2012 Oct 22;5:67. doi: 10.1186/1756-8722-5-67.

6.

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J.

Health Technol Assess. 2012;16(37):1-253, iii-iv. Review.

7.

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.

Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR.

Cancer. 2014 Jun 15;120(12):1830-7. doi: 10.1002/cncr.28659. Epub 2014 Mar 25.

8.

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators.

Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1.

PMID:
21724462
9.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
10.

Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.

Jaime-Pérez JC, Gamboa-Alonso CM, Vázquez-Mellado de Larracoechea A, Rodríguez-Martínez M, Gutiérrez-Aguirre CH, Marfil-Rivera LJ, Gómez-Almaguer D.

Arch Med Res. 2015 Aug;46(6):454-61. doi: 10.1016/j.arcmed.2015.07.004. Epub 2015 Jul 31.

PMID:
26235285
11.

[Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].

Xiong W, Yi S, Li H, Liu H, Li Z, Lü R, Liu W, Zou D, Qiu L.

Zhonghua Yi Xue Za Zhi. 2015 Nov 24;95(44):3593-7. Chinese.

PMID:
26813371
12.

Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.

Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI.

Br J Haematol. 2014 Aug;166(4):514-20. doi: 10.1111/bjh.12915. Epub 2014 Apr 25.

PMID:
24761968
13.

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD.

Ann Oncol. 2012 Sep;23(9):2356-62. doi: 10.1093/annonc/mdr620. Epub 2012 Feb 22.

PMID:
22357442
14.

Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.

Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, MacDonald DA, Buckstein R, Lee C, Alzahrani M, Rubinger M, Foley R, Xenocostas A, Sabloff M, Muccilli A, Chua N, Couture F, Larouche JF, Cohen S, Connors JM, Ambler K, Al-Tourah A, Ramadan KM, Kuruvilla J.

J Clin Oncol. 2013 Mar 20;31(9):1164-71. doi: 10.1200/JCO.2012.44.0693. Epub 2013 Feb 11.

PMID:
23401459
15.

Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.

Sarkozy C, Baseggio L, Feugier P, Callet-Bauchu E, Karlin L, Seymour JF, Lebras L, Michallet AS, Offner F, Dumas O, Traverse-Glehen A, Ffrench M, Lopez-Guillermo A, Berger F, Coiffier B, Felman P, Salles G.

Br J Haematol. 2014 Mar;164(5):659-67. doi: 10.1111/bjh.12675. Epub 2013 Nov 26.

PMID:
24274024
16.

Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.

King MT, Donaldson SS, Link MP, Natkunam Y, Advani RH, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):67-75. doi: 10.1016/j.ijrobp.2015.02.001.

PMID:
25863755
17.

Anthracycline-containing regimens for treatment of follicular lymphoma in adults.

Itchaki G, Gafter-Gvili A, Lahav M, Vidal L, Raanani P, Shpilberg O, Paul M.

Cochrane Database Syst Rev. 2013 Jul 7;(7):CD008909. doi: 10.1002/14651858.CD008909.pub2. Review.

PMID:
23832787
18.

Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.

Zinzani PL, Pellegrini C, Broccoli A, Casadei B, Argnani L, Pileri S.

Am J Hematol. 2013 Nov;88(11):E273-6. doi: 10.1002/ajh.23540. Epub 2013 Aug 30.

19.

Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.

Hainsworth JD, Greco FA, Raefsky EL, Thompson DS, Lunin S, Reeves J Jr, White L, Quinn R, DeBusk LM, Flinn IW.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):277-83. doi: 10.1016/j.clml.2014.02.010. Epub 2014 Feb 28.

PMID:
24679633
20.

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC.

Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4.

PMID:
24602760

Supplemental Content

Support Center